These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37822316)

  • 1. Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan.
    Alewaidat H; Bataineh Z; Bani-Ahmad M; Alali M; Almakhadmeh A
    F1000Res; 2023; 12():741. PubMed ID: 37822316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical policy and innovation for rare diseases: A narrative review.
    Alonso Ruiz A; Large K; Moon S; Vieira M
    F1000Res; 2023; 12():211. PubMed ID: 38778810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success.
    Saltonstall P; Ross H; Kim PT
    Milbank Q; 2024 Mar; 102(1):83-96. PubMed ID: 38087888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thoracic imaging tests for the diagnosis of COVID-19.
    Islam N; Salameh JP; Leeflang MM; Hooft L; McGrath TA; van der Pol CB; Frank RA; Kazi S; Prager R; Hare SS; Dennie C; Spijker R; Deeks JJ; Dinnes J; Jenniskens K; Korevaar DA; Cohen JF; Van den Bruel A; Takwoingi Y; van de Wijgert J; Wang J; McInnes MD;
    Cochrane Database Syst Rev; 2020 Nov; 11():CD013639. PubMed ID: 33242342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
    Karas L; Lu CY; Agrawal PB; Asgari MM
    J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
    Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
    Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision Medicines' Impact on Orphan Drug Designation.
    Mueller CM; Rao GR; Miller Needleman KI
    Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thoracic imaging tests for the diagnosis of COVID-19.
    Salameh JP; Leeflang MM; Hooft L; Islam N; McGrath TA; van der Pol CB; Frank RA; Prager R; Hare SS; Dennie C; Spijker R; Deeks JJ; Dinnes J; Jenniskens K; Korevaar DA; Cohen JF; Van den Bruel A; Takwoingi Y; van de Wijgert J; Damen JA; Wang J; ; McInnes MD
    Cochrane Database Syst Rev; 2020 Sep; 9():CD013639. PubMed ID: 32997361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The availability and affordability of orphan drugs for rare diseases in China.
    Gong S; Wang Y; Pan X; Zhang L; Huang R; Chen X; Hu J; Xu Y; Jin S
    Orphanet J Rare Dis; 2016 Feb; 11():20. PubMed ID: 26920579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
    Tafuri G; Bracco A; Grueger J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act.
    Thamer M; Brennan N; Semansky R
    J Health Polit Policy Law; 1998 Apr; 23(2):265-90. PubMed ID: 9565894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of orphan drug policies in treating rare diseases.
    Weerasooriya SU
    Health Info Libr J; 2019 Jun; 36(2):179-184. PubMed ID: 30933412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
    Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
    Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.